罗欣药业(002793) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥662,426,362.85, a decrease of 69.57% compared to ¥2,177,073,849.50 in the same period last year[3] - The net profit attributable to shareholders was a loss of ¥90,235,051.14, representing a decline of 210.47% from a profit of ¥81,679,473.74 in the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥96,280,159.02, down 223.40% from ¥78,023,937.84 in the prior year[3] - Basic and diluted earnings per share were both -¥0.08, a decrease of 233.33% from ¥0.06 in the previous year[3] - The report indicates that there are no major shareholders participating in margin trading[11] - The net profit for the first quarter of 2023 was -¥103,502,385.34, compared to a net profit of ¥85,346,491.18 in the same period last year, indicating a significant decline[19] - The total comprehensive income for the first quarter was -¥106,871,684.61, compared to ¥78,516,671.07 in the previous year[19] Cash Flow and Assets - Operating cash flow net amount was ¥26,850,638.73, a significant improvement of 103.38% from a negative cash flow of ¥794,046,525.88 in the same period last year[3] - Cash received from sales of goods and services was ¥666,158,367.11, a decline of 34.28% from ¥1,013,699,968.16 in the previous year[9] - The company experienced a 1653.24% increase in cash received from investment recoveries, totaling ¥627,658,412.96 compared to ¥35,800,000.00 in the same period last year[9] - Cash and cash equivalents decreased to ¥1,209,542,871.00 from ¥1,433,805,083.16, a decline of approximately 15.6%[16] - The company’s cash and cash equivalents at the end of the period were ¥642,998,306.21, down from ¥853,539,279.03 at the end of the previous year[23] - The cash flow from operating activities generated a net inflow of ¥26,850,638.73, a recovery from a net outflow of -¥794,046,525.88 in the same quarter last year[22] - The net cash flow from investing activities was ¥584,960,373.21, a significant improvement from -¥101,313,880.40 in the previous year[22] - The net cash flow from financing activities was -¥797,934,844.53, compared to a net inflow of ¥262,051,480.05 in the same period last year[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,901[10] - Shandong Luoxin Holdings Co., Ltd. holds 31.23% of shares, totaling 339,699,320 shares, with 232,961,841 shares pledged[10] - The second largest shareholder, Fang Xiubao, holds 9.22% of shares, totaling 100,294,266 shares[10] - The company has a total of 10 major shareholders, with the top three holding a combined 49.92% of shares[10] - The lock-up period for major shareholders, including Fang Xiubao, has expired as of April 8, 2023[12] - The report highlights that there are no significant changes in shareholder relationships or actions taken during the reporting period[11] Operational Metrics - The company reported a 60.08% decrease in operating costs, amounting to ¥354,968,739.84 compared to ¥889,220,510.10 in the same period last year[9] - Total operating costs amounted to ¥752,691,953.36, down from ¥1,979,311,251.95, indicating a reduction of about 61.9%[18] - Operating profit for the period was a loss of ¥99,876,952.75, compared to a profit of ¥102,046,516.84 in the same period last year[18] - The company reported a net loss of ¥99,876,952.75, reflecting a challenging market environment[18] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥7,055,301,154.66, down 13.09% from ¥8,107,824,389.64 at the end of the previous year[3] - Total current assets decreased to ¥3,701,002,863.83 from ¥4,721,892,673.47, a reduction of about 21.5%[16] - Total liabilities decreased to ¥3,845,394,726.62 from ¥4,811,482,861.20, indicating a decline of approximately 20.0%[17] - The company’s total assets decreased to ¥7,055,301,154.66 from ¥8,117,960,973.82, a reduction of about 13.1%[17] - Long-term investments increased slightly to ¥173,072,660.76 from ¥170,562,950.76, showing a growth of approximately 2.9%[16] Research and Development - Research and development expenses were ¥38,888,009.55, down from ¥57,073,032.40, reflecting a decrease of about 31.8%[18] - The company has not disclosed any new product developments or technological advancements in the current report[15] Future Outlook - The financial report does not provide specific performance guidance or future outlook[15] - There is no mention of market expansion or mergers and acquisitions in the latest financial report[15] Audit Information - The company did not conduct an audit for the first quarter report[24]